|
MATK |
megakaryocyte-associated tyrosine kinase |
- Downregulation of ERBB2 signaling
|
|
|
|
MDM2 |
MDM2 proto-oncogene |
- AKT phosphorylates targets in the cytosol
- Oxidative Stress Induced Senescence
- Oncogene Induced Senescence
- SUMOylation of transcription factors
- SUMOylation of ubiquitinylation proteins
- Trafficking of AMPA receptors
- Constitutive Signaling by AKT1 E17K in Cancer
- Ub-specific processing proteases
- Regulation of TP53 Activity through Phosphorylation
- Regulation of TP53 Degradation
- Regulation of TP53 Activity through Methylation
- Stabilization of p53
- Regulation of RUNX3 expression and activity
- Signaling by ALK fusions and activated point mutants
- Degradation of CDH1
- NPAS4 regulates expression of target genes
|
- Zinc
- Cis-[4,5-Bis-(4-Bromophenyl)-2-(2-Ethoxy-4-Methoxyphenyl)-4,5-Dihydroimidazol-1-Yl]-[4-(2-Hydroxyethyl)Piperazin-1-Yl]Methanone
- Cis-[4,5-Bis-(4-Chlorophenyl)-2-(2-Isopropoxy-4-Methoxyphenyl)-4,5-Dihyd Roimidazol-1-Yl]-Piperazin-1-Yl-Methanone
- Zinc acetate
- Zinc chloride
- Zinc sulfate, unspecified form
|
- Penile cancer
- Alveolar rhabdomyosarcoma
- Choriocarcinoma
- Osteosarcoma
- Glioma
|
|
MED28 |
mediator complex subunit 28 |
- PPARA activates gene expression
- Transcriptional regulation of white adipocyte differentiation
- Transcriptional regulation of white adipocyte differentiation
- RSV-host interactions
|
|
|
|
MET |
MET proto-oncogene, receptor tyrosine kinase |
- PIP3 activates AKT signaling
- Constitutive Signaling by Aberrant PI3K in Cancer
- Sema4D mediated inhibition of cell attachment and migration
- RAF/MAP kinase cascade
- MET Receptor Activation
- Negative regulation of MET activity
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- MET activates RAS signaling
- MET activates PI3K/AKT signaling
- MET activates PTPN11
- MET activates PTK2 signaling
- InlB-mediated entry of Listeria monocytogenes into host cell
- InlB-mediated entry of Listeria monocytogenes into host cell
- MET interacts with TNS proteins
- MET activates RAP1 and RAC1
- MET receptor recycling
- MET activates STAT3
- MECP2 regulates neuronal receptors and channels
- Drug-mediated inhibition of MET activation
- Regulation of MITF-M-dependent genes involved in cell cycle and proliferation
|
- Sunitinib
- K-252a
- SGX-523
- 1-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-2-oxo-1,2-dihydropyridine-3-carboxamide
- N-({4-[(2-aminopyridin-4-yl)oxy]-3-fluorophenyl}carbamoyl)-2-(4-fluorophenyl)acetamide
- 2-(4-fluorophenyl)-N-{[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]carbamoyl}acetamide
- N-(3-chlorophenyl)-N-methyl-2-oxo-3-[(3,4,5-trimethyl-1H-pyrrol-2-yl)methyl]-2H-indole-5-sulfonamide
- 3-[3-(4-methylpiperazin-1-yl)-7-(trifluoromethyl)quinoxalin-5-yl]phenol
- AMG-208
- 1-[(2-NITROPHENYL)SULFONYL]-1H-PYRROLO[3,2-B]PYRIDINE-6-CARBOXAMIDE
- Crizotinib
- Cabozantinib
- Capmatinib
- Tivozanib
- Fostamatinib
- Tivantinib
- Brigatinib
- Amuvatinib
- Tepotinib
- Amivantamab
|
- Cholangiocarcinoma
- Gastric cancer
- Renal cell carcinoma
|
|
MICAL1 |
microtubule associated monooxygenase, calponin and LIM domain containing 1 |
- Factors involved in megakaryocyte development and platelet production
|
|
|
|
MPZL1 |
myelin protein zero like 1 |
|
|
|
|
MST1R |
macrophage stimulating 1 receptor |
|
|
|
|
MT-ND2 |
NADH dehydrogenase subunit 2 |
- Mitochondrial translation termination
- Respiratory electron transport
- Complex I biogenesis
- Mitochondrial protein degradation
|
|
- Leber optic atrophy; Leber hereditary optic atrophy (LHON)
|
|
MUC1 |
mucin 1, cell surface associated |
- Defective GALNT3 causes HFTC
- Defective C1GALT1C1 causes TNPS
- Defective GALNT12 causes CRCS1
- Dectin-2 family
- Interleukin-4 and Interleukin-13 signaling
- O-linked glycosylation of mucins
- Termination of O-glycan biosynthesis
- Developmental Lineage of Mammary Gland Luminal Epithelial Cells
- Developmental Lineage of Mammary Gland Alveolar Cells
|
|
|
|
MYLK |
myosin light chain kinase |
- Smooth Muscle Contraction
- RHO GTPases activate PAKs
- RHO GTPases activate PAKs
|
|
- Familial thoracic aortic aneurysm and dissection (TAAD); Aortic aneurysm familial thoracic type (AAT)
|
|
NANS |
N-acetylneuraminate synthase |
|
|
|
|
NCOA6 |
nuclear receptor coactivator 6 |
- BMAL1:CLOCK,NPAS2 activates circadian expression
- PPARA activates gene expression
- PPARA activates gene expression
- Transcriptional activation of mitochondrial biogenesis
- Activation of gene expression by SREBF (SREBP)
- Transcriptional regulation of white adipocyte differentiation
- Regulation of lipid metabolism by PPARalpha
- Activation of anterior HOX genes in hindbrain development during early embryogenesis
- Cytoprotection by HMOX1
- Heme signaling
- Formation of WDR5-containing histone-modifying complexes
- Epigenetic regulation of gene expression by MLL3 and MLL4 complexes
- MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis
- MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis
- Expression of BMAL (ARNTL), CLOCK, and NPAS2
- RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression
|
|
|
|
NEDD4 |
NEDD4 E3 ubiquitin protein ligase |
- ISG15 antiviral mechanism
- Downregulation of ERBB4 signaling
- Regulation of PTEN localization
- Regulation of PTEN stability and activity
- Antigen processing: Ubiquitination & Proteasome degradation
|
|
|
|
NFKBIA |
NFKB inhibitor alpha |
- Activation of NF-kappaB in B cells
- RIP-mediated NFkB activation via ZBP1
- Downstream TCR signaling
- NF-kB is activated and signals survival
- FCERI mediated NF-kB activation
- TAK1-dependent IKK and NF-kappa-B activation
- SUMOylation of immune response proteins
- IkBA variant leads to EDA-ID
- CLEC7A (Dectin-1) signaling
- Ub-specific processing proteases
- Interleukin-1 signaling
- TRAF6 mediated NF-kB activation
- SARS-CoV-1 activates/modulates innate immune responses
- Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells
|
- Acetylsalicylic acid
- Bardoxolone methyl
- Astaxanthin
|
- Hodgkin lymphoma
- Ectodermal dysplasia associated immunodeficiency (EDA-ID), including the following two diseases: NF-kappa-B essential modulator (NEMO) defect; Inhibitor of kappa-B (I-kappa-B) defect
|
|
NMT1 |
N-myristoyltransferase 1 |
- Late Phase of HIV Life Cycle
- eNOS activation
- Inactivation, recovery and regulation of the phototransduction cascade
- Activation, myristolyation of BID and translocation to mitochondria
|
- (1-Methyl-1h-Imidazol-2-Yl)-(3-Methyl-4-{3-[(Pyridin-3-Ylmethyl)-Amino]-Propoxy}-Benzofuran-2-Yl)-Methanone
|
|
|
NOS2 |
nitric oxide synthase 2 |
- ROS and RNS production in phagocytes
- Nitric oxide stimulates guanylate cyclase
- Interleukin-4 and Interleukin-13 signaling
- Peroxisomal protein import
- Peroxisomal protein import
- Inhibition of nitric oxide production
|
- Arginine
- Citrulline
- Mesalazine
- Minocycline
- Miconazole
- Dexamethasone
- Ginkgo biloba
- N,N-dimethylarginine
- 4R-Fluoro-N6-ethanimidoyl-L-lysine
- 3-Bromo-7-Nitroindazole
- N-[3-(aminomethyl)benzyl]acetamidine
- 7-Nitroindazole
- S-Ethylisothiourea
- Thiocoumarin
- N-omega-propyl-L-arginine
- 6-Nitroindazole
- N(5)-[(hydroxyamino)(imino)methyl]-L-ornithine
- Imidazole
- N-(4-{2-[(3-chlorobenzyl)amino]ethyl}phenyl)thiophene-2-carboximidamide
- Thiocitrulline
- L-erythro-7,8-dihydrobiopterin
- 5-Nitroindazole
- KD7040
- Fenoxaprop-ethyl
- Pimagedine
- 5-(4'-AMINO-1'-ETHYL-5',8'-DIFLUORO-1'H-SPIRO[PIPERIDINE-4,2'-QUINAZOLINE]-1-YLCARBONYL)PICOLINONITRILE
- N-[2-(1,3-BENZODIOXOL-5-YL)ETHYL]-1-[2-(1H-IMIDAZOL-1-YL)-6-METHYLPYRIMIDIN-4-YL]-D-PROLINAMIDE
- 4-({4-[(4-methoxypyridin-2-yl)amino]piperidin-1-yl}carbonyl)benzonitrile
- (2S)-2-methyl-2,3-dihydrothieno[2,3-f][1,4]oxazepin-5-amine
- (3R)-3-[(1,2,3,4-tetrahydroisoquinolin-7-yloxy)methyl]-2,3-dihydrothieno[2,3-f][1,4]oxazepin-5-amine
- 4-(1,3-BENZODIOXOL-5-YLOXY)-2-[4-(1H-IMIDAZOL-1-YL)PHENOXY]PYRIMIDINE
- (3S)-1-(1,3-BENZODIOXOL-5-YLMETHYL)-3-[4-(1H-IMIDAZOL-1-YL)PHENOXY]PIPERIDINE
- 4-(1,3-BENZODIOXOL-5-YLOXY)-2-[4-(1H-IMIDAZOL-1-YL)PHENOXY]-6-METHYLPYRIMIDINE
- ETHYL 4-[(4-CHLOROPYRIDIN-2-YL)AMINO]PIPERIDINE-1-CARBOXYLATE
- N-[2-(4-AMINO-5,8-DIFLUORO-1,2-DIHYDROQUINAZOLIN-2-YL)ETHYL]-3-FURAMIDE
- ETHYL 4-[(4-METHYLPYRIDIN-2-YL)AMINO]PIPERIDINE-1-CARBOXYLATE
- N-[2-(6-AMINO-4-METHYLPYRIDIN-2-YL)ETHYL]-4-CYANOBENZAMIDE
- 1-(6-CYANO-3-PYRIDYLCARBONYL)-5',8'-DIFLUOROSPIRO[PIPERIDINE-4,2'(1'H)-QUINAZOLINE]-4'-AMINE
- 4-(1H-IMIDAZOL-1-YL)PHENOL
- 1-[4-(AMINOMETHYL)BENZOYL]-5'-FLUORO-1'H-SPIRO[PIPERIDINE-4,2'-QUINAZOLIN]-4'-AMINE
- Triflusal
- Levamlodipine
- Dipyrithione
- Dexamethasone acetate
|
|
|
NPHS1 |
NPHS1 adhesion molecule, nephrin |
- Nephrin family interactions
- Nephrin family interactions
|
|
- Nephrotic syndrome and focal segmental glomerulosclerosis
|
|
NR1I2 |
nuclear receptor subfamily 1 group I member 2 |
|
- Vitamin E
- Oxiconazole
- Phenytoin
- Diethylstilbestrol
- Clotrimazole
- Pentobarbital
- Spironolactone
- Lindane
- Flutamide
- Ritonavir
- Erlotinib
- Cyclophosphamide
- Mephenytoin
- Carbamazepine
- Tamoxifen
- Warfarin
- Ethotoin
- Estradiol
- Mifepristone
- Methylphenobarbital
- Ethinylestradiol
- Ketoconazole
- Fenofibrate
- Rifampicin
- Clonazepam
- Miconazole
- Nifedipine
- Econazole
- Sulfinpyrazone
- Phenobarbital
- Ifosfamide
- Rifaximin
- Paclitaxel
- Dexamethasone
- Docetaxel
- Bezafibrate
- Genistein
- Prasterone
- Hyperforin
- Resveratrol
- Pregnenolone
- Quercetin
- SR12813
- Afimoxifene
- Phenolphthalein
- Permethrin
- Dovitinib
- Chenodeoxycholic acid
- TO-901317
- Hexestrol
- Triclosan
- Rilpivirine
- Pyrethrum extract
- Myrrh
- Piperine
- Troleandomycin
- Fenofibric acid
- Estradiol acetate
- Estradiol benzoate
- Estradiol cypionate
- Estradiol dienanthate
- Estradiol valerate
- alpha-Tocopherol succinate
- D-alpha-Tocopherol acetate
- Dexamethasone acetate
|
|
|
NR1I3 |
nuclear receptor subfamily 1 group I member 3 |
|
- Doxylamine
- Meclizine
- Ketoconazole
- Atorvastatin
- Pheniramine
- Prasterone
- 16,17-Androstene-3-Ol
- Resveratrol
- Cholesterol
- Phenolphthalein
- 3,20-Pregnanedione
- Hexestrol
- Triclosan
|
|
|
NR3C1 |
nuclear receptor subfamily 3 group C member 1 |
- HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand
- SUMOylation of intracellular receptors
- PTK6 Expression
- Regulation of RUNX2 expression and activity
- FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes
- Potential therapeutics for SARS
- Regulation of NPAS4 gene transcription
|
- Flunisolide
- Diflorasone
- Alclometasone
- Medrysone
- Amcinonide
- Fluorometholone
- Megestrol acetate
- Levonorgestrel
- Beclomethasone dipropionate
- Progesterone
- Spironolactone
- Betamethasone
- Desoximetasone
- Fluticasone propionate
- Fluocinolone acetonide
- Ulobetasol
- Triamcinolone
- Prednisone
- Flumethasone
- Fludrocortisone
- Norethisterone
- Hydrocortisone
- Mometasone
- Hydrocortamate
- Mifepristone
- Clocortolone
- Flurandrenolide
- Prednisolone
- Loteprednol etabonate
- Rimexolone
- Methylprednisolone
- Clobetasol propionate
- Fluocinonide
- Prednicarbate
- Fluoxymesterone
- Budesonide
- Dexamethasone
- Desonide
- Cortisone acetate
- Paramethasone
- Drospirenone
- Ciclesonide
- Hexane-1,6-Diol
- Aldosterone
- ORG-34517
- Difluprednate
- Ulipristal
- Fluticasone furoate
- Tixocortol
- Difluocortolone
- Gestrinone
- Deflazacort
- Onapristone
- Cortivazol
- Clobetasone
- Fluticasone
- Mometasone furoate
- Hydrocortisone aceponate
- Hydrocortisone acetate
- Hydrocortisone butyrate
- Hydrocortisone cypionate
- Hydrocortisone phosphate
- Hydrocortisone probutate
- Hydrocortisone valerate
- Segesterone acetate
- Prednisolone phosphate
- Dexamethasone acetate
- Betamethasone phosphate
- Prednisolone acetate
|
- 46,XX disorders of sex development (Disorders related to androgen excess), including: Congenital adrenal hyperplasias; Glucocorticoid resistance; Aromatase deficiency
|